Parasitic Infections in HIV-Infected Patients

  • Authors: José M. Miró, MD, PhD; Miriam J. Álvarez-Martínez, MD, PhD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/20/21 (What's New)

Summary

  • Secondary prophylaxis should be administered to all patients who have completed initial therapy for toxoplasmic encephalitis (Table 4)[CDC OI; EACS]
  • Preferred regimen is pyrimethamine plus sulfadiazine plus leucovorin (folinic acid)
  • Prophylaxis can be discontinued if the patient’s CD4+ cell count increases to > 200 cells/mm3 with use of ART for > 6 months and HIV-1 RNA remains undetectable (Table 5)[CDC OI; EACS; Miro 2006]

Action required

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.